Hi Folks,Good article on Renalytix here summarizing their...

Hi Folks,

Good article on Renalytix here summarizing their progress to date: https://seekingalpha.com/article/4478063-renalytix-laying-foundations-for-growth

Also note, Renalytix recently partnered with the ADA, I think this is an excellent demonstration of industry acceptance of predictive testing and will bode well for PromarkerD once available in the U.S.

The ADA will increase awareness of KidneyIntelX, once health care professionals start becoming familiar with these predictive tests and incorporate them into standard of care, I strongly believe PromarkerD will be the preferred test, it has a longer history of clinical validation, does not requiring electronic medical records and is significantly cheaper.

I have my eyes on 4 major catalysts this year:

1. Endometriosis interim results (due Q1)
2. US Licensing Deal with major diagnostics company for lab developed test kit & subsequent CPT application
3. FDA submission for the In Vitro test kit
4. Capital raise (my prediction is May) note there is ~$2M of options expiring this year. Fingers crossed for a SPP

Of course lots of other news expected from the pipeline as well:

	Test	Stage
1	PromarkerD	Commercialization
2	Endometriosis	Pending Validation study
3	Giardia	Validation study results under analysis
4	Asthma & COPD	Results from Proof-of-Concept study under analysis.
5	Plant dieback	Results from Discovery study under analysis
6	Diabetic retinopathy	Unsuccessful - see https://www.sciencedirect.com/science/article/abs/pii/S1056872721000076
7	Oxidative stress (2-tag)	Validation studies pending; Commercialization discussions underway.
8	Oesophageal cancer	Technology transfer ongoing; Clinical Validation pending.
9	COVID	Suspended/Cancelled

Cheers